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Abstract
Background: Urinary bladder cancer is a common malignancy worldwide, and outcomes for patients with
advanced bladder cancer remain poor. Antiproliferative factor (APF) is a potent glycopeptide inhibitor of epithelial
cell proliferation that was discovered in the urine of patients with interstitial cystitis, a disorder with bladder
epithelial thinning and ulceration. APF mediates its antiproliferative activity in primary normal bladder epithelial
cells via cytoskeletal associated protein 4 (CKAP4). Because synthetic asialo-APF (as-APF) has also been shown to
inhibit T24 bladder cancer cell proliferation at nanomolar concentrations in vitro, and because the peptide segment
of APF is 100% homologous to part of frizzled 8, we determined whether CKAP4 mediates as-APF inhibition of
proliferation and/or downstream Wnt/frizzled signaling events in T24 cells.
Methods: T24 cells were transfected with double-stranded siRNAs against CKAP4 and treated with synthetic as-APF
or inactive control peptide; cells that did not undergo electroporation and cells transfected with non-target
(scrambled) double-stranded siRNA served as negative controls. Cell proliferation was determined by
3H-thymidine
incorporation. Expression of Akt, glycogen synthase kinase 3b (GSK3b), b-catenin, p53, and matrix metalloproteinase
2 (MMP2) mRNA was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Akt,
GSK-3b, MMP2, b-catenin, and p53 protein expression, plus Akt, GSK-3b, and b-catenin phosphorylation, were
determined by Western blot.
Results: T24 cell proliferation, MMP2 expression, Akt ser473 and thr308 phosphorylation, GSK3b tyr216
phosphorylation, and b-catenin ser45/thr41 phosphorylation were all decreased by APF, whereas p53 expression,
and b-catenin ser33,37/thr41 phosphorylation, were increased by APF treatment in non-electroporated and non-
target siRNA-transfected cells. Neither mRNA nor total protein expression of Akt, GSK3b,o rb-catenin changed in
response to APF in these cells. In addition, the changes in cell proliferation, MMP2/p53 mRNA and protein
expression, and Akt/GSK3b/b-catenin phosphorylation in response to APF treatment were all specifically abrogated
following CKAP4 siRNA knockdown.
Conclusions: Synthetic as-APF inhibits cell proliferation in T24 bladder carcinoma cells via the CKAP4 receptor. The
mechanism for this inhibition involves regulating phosphorylation of specific cell signaling molecules (Akt, GSK3b,
and b-catenin) plus mRNA and protein expression of p53 and MMP2.
Background
Bladder cancer is the second most common genitourin-
ary malignancy and the fourth most common malig-
nancy in men in the United States, causing over 12,000
deaths annually [1]. Although seventy percent of cases
are diagnosed in the superficial stage, up to 30% can
present with or develop muscle-invasive disease, and
long term outcomes for patients with advanced bladder
cancer remain poor [2,3]. Additional treatments that
prevent or control the progression of bladder carcinoma
are therefore sorely needed.
Altered expression of certain genes commonly found
in human carcinomas are also found in bladder cancer,
including decreased expression of E-cadherin [4-8] and
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increased expression of heparin-binding epidermal
growth factor-like growth factor (HB-EGF) [12]. Of
these abnormalities, decreased E-cadherin and
increased HB-EGF expression appear to be particularly
closely associated with increased tumor progression,
cell proliferation, and/or metastasis [5-8,12-15]. Thera-
pies aimed at controlling the aberrant expression of
genes associated with tumor progression and metasta-
sis in bladder carcinoma cells may be helpful for con-
trolling disease.
Our laboratory previously discovered a natural anti-
proliferative factor (APF) [16-18] that profoundly inhi-
bits bladder epithelial cell proliferation [19,20],
upregulates E-cadherin [21], p53 and p21 [22] expres-
sion, and inhibits the production of other cell proteins
including HB-EGF [17,20,21,23]. APF is secreted specifi-
cally by bladder epithelial cells from patients with inter-
stitial cystitis (IC), a chronic bladder disorder
characterized by bladder epithelial thinning and/or
ulceration [24-26]. APF is a low molecular weight
frizzled 8-related glycopeptide that inhibits both normal
and IC bladder epithelial cell proliferation via cytoskele-
ton associated protein 4 (CKAP4, also known as
CLIMP-63 and ERGIC-63) [27], a type II transmem-
brane receptor [28] whose palmitoylation appears to be
required for mediating APF activity in HeLa cells [29].
Synthetic asialo-APF (as-APF) inhibits T24 bladder car-
cinoma cell proliferation in vitro at low (nanomolar)
concentrations similar to those required for inhibition of
normal bladder epithelial cell proliferation [19]. How-
ever, neither the role of CKAP4 in regulation of bladder
carcinoma cell proliferation, nor its role in mediating
APF activity in bladder carcinoma cells, has yet been
studied.
Therefore, to better understand the mechanism by
which APF regulates T24 bladder carcinoma cell prolif-
eration, we determined the effect of as-APF on the
expression or activation of enzymes involved in wingless-
int (Wnt)/frizzled signaling (including AKR-transforming
enzyme (Akt), glycogen synthase kinase-3 beta (GSK3b),
b-catenin, and matrix metalloprotease 2 (MMP2), as
well as the role of CKAP4 in mediating as-APF activity in
T24 cells.
Methods
Cell Culture
T24 human urinary bladder cancer cells (ATCC HTB-4)
were grown to 60-80% confluence in McCoy’s 5A medium
(Invitrogen, Carlsbad, CA) containing 10% heat-
inactivated fetal bovine serum (FBS), 1% antibiotic/antimy-
cotic solution, 1% L-glutamine (all from Sigma, St. Louis,
MO) and 2.2 grams/L sodium bicarbonate (Invitrogen), in
a 37°C/5% CO2 atmosphere.
siRNA Transfection
Double-stranded siRNA corresponding to nucleotides
594-616 of CKAP4 (5’-AACUUUUGAGUCCAUCUU
GAGAA-3’ sense strand) and a scrambled double-
stranded negative control siRNA (5’-AAUUCUGUAUG
CUACCUGUAGAA-3’ sense strand) were prepared by
preincubating single-stranded sense and antisense
strands prepared with double A overhangs in serum-free
McCoy’s 5A medium at 37°C for 1 hour. T24 human
bladder cancer cells were trypsinized for 10 minutes at
room temperature, centrifuged in growth medium (as
defined above), and the cell pellet was resuspended in
serum-free medium at a density of 1 × 10
6 cells/ml.
Two hundred microliters of the cell suspension were
then transferred to a sterile 2-mm cuvette with 14 μgo f
CKAP4 siRNA, scrambled non-target siRNA, or no
siRNA, and electroporated at 160 V/500 microfarad
capacitance using a Bio-Rad Gene Pulser Xcell. The
cells were then immediately transferred to T75 cell cul-
ture flasks (Corning Incorporated, Corning, NY) (for
extraction of RNA and protein) or to 96 well tissue cul-
ture plates (Corning Incorporated) (for the cell prolifera-
tion assay) and incubated in growth medium overnight
in a 37°C/5% CO2 atmosphere.
APF Treatment (for RNA and Protein Extraction)
Following overnight incubation in growth medium,
transfected T24 human bladder cancer cells were further
incubated with serum-free McCoy’s5 Am e d i u mf o rt h e
next 24 hours, after which they were treated with
500 nM as-APF or 500 nM inactive nonglycosylated
peptide control (both from PolyPeptide Laboratories,
Incorporated, San Diego, CA). Cells were then incubated
for an additional 48 hrs in a 37°C/5% CO2 atmosphere
prior to RNA and protein extraction.
RNA Extraction
Following cell incubation with as-APF or its control
peptide/diluent, the culture medium was removed, T24
cells were washed with 1× PBS, and RNA was extracted
using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. RNA con-
centration was measured at 260 nM in a UV/VIS spec-
trophotometer from Perkin Elmer. Extracted RNA was
stored at -80°C.
Protein Extraction
Cell culture medium was removed from duplicate flasks,
T24 cells were scraped into ice-cold PBS, and the cell
slurry was centrifuged at 4°C for 5 minutes at 2000 rpm.
Supernatant was then removed and the pellet was washed
with ice-cold PBS and centrifuged again at 4°C for 5 min-
utes at 2000 rpm. This pellet was then resuspended in ice-
cold RIPA buffer (Upstate Cell Signaling Solutions,
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Cocktail (Roche, Indianapolis, IN) and centrifuged at
14,000 rpm for 15 minutes at 4°C. Supernatant containing
total cell protein was collected and stored at -80°C.
3H-Thymidine Cell Proliferation Assay
Cell proliferation was measured by
3H-thymidine incor-
poration into T24 human bladder cancer cells, plating
1.5 ×10
3 cells/well onto a 96-well cell culture plate
(Corning Incorporated), in 150 μL/well McCoy’s5 A
medium containing 10% heat inactivated FBS, 1% anti-
biotic/antimycotic solution, 1% L-glutamine, and plus
2.2 grams/L sodium bicarbonate. The next day, cell
growth medium was removed and replaced with 100 μl
serum-free McCoy’sm e d i u m .O nt h et h i r dd a y ,s y n -
thetic as-APF was resuspended in acetonitrile/distilled
water (1:1) and applied to the cells in serum-free
McCoy’s medium at varying concentrations; cell con-
trols received acetonitrile/distilled water diluted in
serum-free McCoy’s medium (same final concentration
of diluent). Cells were then incubated at 37°C in a 5%
CO2 atmosphere for an additional 48 hours, after which
they were labeled with 1 μCi per well
3H-thymidine at
37°C in a 5% CO2 atmosphere for 4 hours. The cells
were then treated with trypsin-EDTA (Invitrogen), inso-
luble cell contents harvested and methanol-fixed onto
glass fiber filter paper, and the amount of radioactivity
incorporated determined using a Beckman scintillation
counter. Significant inhibition of
3H-thymidine incor-
poration was defined as a decrease in cpm of >2 SD
from the mean of control cells for each plate.
Real-time qRT-PCR
Gene expression was determined using SYBR® Green
based real-time RT-PCR, QuantiTect® primers and
reagents (Qiagen) and a Roche 480 LightCycler. Samples
were tested in triplicate runs, and specific mRNA levels
quantified and compared to mRNA levels for b-actin or
GAPDH using Roche LC480 real-time PCR analysis soft-
ware (version 1.5.0). Predetermined optimal concentra-
tions of RNA were used for each set of primers. p53
(QT00060235), Akt (QT00085379), GSK3b (QT000
57134), b-catenin (QT00077882), MMP2 (QT00088396),
GAPDH (QT01192646), and b-actin (QT1680476) primer
sets were obtained from Qiagen. p53 served as a standard
control for APF activity, while GAPDH and b-actin served
as standard controls for the qRT-PCR procedure.
SDS Polyacrylamide Gel Electrophoresis and Western Blot
Assay
Specific protein expression or phosphorylation was deter-
mined by Western blot. Protein concentration was
measured using a Folin reagent-based protein assay kit
(Bio-Rad, Hercules, CA). Solubilized cell proteins were
incubated for 10 min at 70°C in sample reducing buffer,
each lane was loaded with 30 μg of protein, and proteins
were separated by electrophoresis using 4-12% NuPAGE
NOVEX BisTris polyacrylamide gels (Invitrogen) in
MOPS/SDS running buffer (Invitrogen), according to the
manufacturer’s instructions. Proteins were then trans-
ferred to nitrocellulose membranes (Invitrogen) according
to the NuPAGE gel manufacturer’s protocol for Western
transfer (30 V constant voltage for 1 h). Following protein
transfer, the nitrocellulose membranes were blocked with
5% nonfat dry milk in TBS-T buffer (Tris-buffered saline,
pH 7.4, with 0.1% Tween 20) and incubated overnight at 4°
C in TBS-T buffer containing mouse monoclonal anti-
CKAP4 ("anti-CLIMP-63,” clone G1/296) (Alexis Biochem-
ical, Plymouth Meeting, PA), anti-p53 (Calbiochem, San
Diego, CA), anti-GSK3b (BD Biosciences, San Jose, CA),
anti-phosphoGSK3b (tyr 216) (BD Biosciences), or anti-b
actin (Sigma) antibodies; or rabbit polyclonal anti-MMP2,
anti-Akt, anti-phosphoAkt (ser473/thr308), anti-phos-
phoGSK3b (ser9), anti-b-catenin, anti-phosphob-
catenin (ser 33,37/thr 41), or anti-phosphob-catenin (ser
45/thr 41) (all obtained from Cell Signaling Technology,
Danvers, MA). When more than one antibody was used for
binding to proteins on a single membrane, the membrane
was stripped between antibody incubations using Restore
PLUS Western blot stripping buffer (Pierce, Rockford, IL)
according to the manufacturer’s instructions. The mem-
branes were subsequently washed three times with TBS-T,
incubated with horseradish peroxidase-conjugated goat
anti-mouse or goat anti-rabbit IgG secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at
room temperature, and developed with ECL chemilumines-
cence Reagent (Amersham Biosciences, Piscataway, NJ).
p53 expression served as a positive control for APF activity;
b-actin expression served as a standard control for the
Western blot procedure.
Statistical Analysis
Significant inhibition of
3H-thymidine incorporation was
defined as a mean decrease in cpm of ± 2 SD from the
mean of control cells for each plate. Crossover point
analysis was performed for qRT-PCR data, and mRNA
copy number for each gene was quantified relative to
b-actin; this value is expressed as mean ± standard error
of the mean (SEM) for duplicate runs performed on
three separate occasions. The significance of the differ-
ence between mean values was determined by an analy-
sis of variance with p < .05 considered significant.
Results
siRNA knockdown of CKAP4 expression inhibits APF
antiproliferative activity in T24 bladder carcinoma cells
To determine whether APF activity was mediated by
CKAP4 in T24 cells, expression of this receptor was
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via electroporation. Non-target (scrambled) siRNA was
used to confirm the specificity of CKAP4 knockdown,
and untreated cells served as negative controls for the
electroporation procedure. Decreased CKAP4 protein
expression following CKAP4 siRNA transfection was
confirmed by Western blot (Figure 1A). As shown in
Figure 1B, dose-dependent inhibition of T24 cell prolif-
eration by submicromolar concentrations of as-APF was
specifically and significantly decreased following CKAP4
knockdown (p < .001 for comparison of CKAP siRNA-
treated cells compared to both controls at concentra-
tions ≥ 1.25 nM), indicating the importance of this
receptor for mediating APF antiproliferative activity in
T24 bladder carcinoma cells.
APF increases p53 tumor suppressor gene expression via
CKAP4 in T24 cells
HPLC-purified native APF was previously shown to sig-
nificantly decrease cell cycle transit and increase p53
expression in both normal human urothelial cells and
T24 bladder carcinoma cells in vitro, while p53 knock-
down decreased the antiproliferative effects of APF [22].
To determine whether CKAP4 mediated APF’s stimula-
tion of p53 expression, T24 cells were treated with
500 nM synthetic as-APF or its inactive peptide control
and the effects on p53 mRNA and protein expression
examined. As shown in Figure 2A, p53 protein expres-
sion was increased in APF-treated (as compared to con-
trol peptide-treated) nontransfected cells. Similarly, p53
protein expression was also increased in response to APF
in cells transfected with non-target siRNA, whereas p53
levels changed less in response to APF following CKAP4
knockdown (Figure 2A). qRT-PCR also showed signifi-
cantly increased p53 mRNA expression following APF
treatment of nontransfected or non-target siRNA-trans-
fected, but not CKAP4 siRNA-transfected, cells (Figure
2B-D) (p < .01 for both nontransfected and non-target
transfected cells, and target gene mRNA relative to
b-actin or GAPDH mRNA; data shown for normalization
to b-actin expression, only). These findings indicate that
CKAP4 also mediates the effects of APF on p53 mRNA
and protein expression in T24 cells.
Decreased Akt (serine 473 and threonine 308)
phosphorylation following APF treatment of T24 cells
To understand whether Wnt/frizzled signaling might
p l a yar o l ei nm e d i a t i n gA P Fa c t i v i t yi nT 2 4c e l l s ,w e
determined the effect(s) of as-APF treatment on Akt
expression and serine/threonine phosphorylation in
nontransfected, non-target siRNA-transfected, and
CKAP4 siRNA-transfected cells. As shown in Figure 3A,
APF treatment caused decreased Akt serine 473 (ser473)
and threonine 308 (thr308) phosphorylation in non-
transfected and non-target siRNA transfected cells,
whereas there was no apparent change in phosphoryla-
tion at either site in CKAP4 siRNA-transfected cells.
However, APF treatment did not appear to affect total
Akt protein (Figure 3A) or Akt mRNA (Figure 3B-D)
expression, regardless of transfection status (p > .05 for
all PCR comparisons, including target gene mRNA rela-
tive to b-actin or GAPDH mRNA; data shown for nor-
malization to b-actin expression, only). These findings
indicate a potential role for inhibition of Akt activation
in CKAP4-mediated APF antiproliferative activity.
Decreased GSK3b (tyrosine 216) and b-catenin (serine 45/
threonine 41) phosphorylation, but increased b-catenin
(serine 33, 37/threonine 41) phosphorylation, in response
to APF
In Wnt signaling pathways, Akt phosphorylation/activa-
tion stimulates GSK3b serine 9 (ser9) phosphorylation,
leading to its inactivation, which in turn inhibits
b-catenin ubiquitination and degradation [30]. We
therefore determined whether APF-induced decreased
Akt phosphorylation lead to changes in GSK3b and
b-catenin phosphorylation in T24 bladder carcinoma
 
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
0
20
40
60
80
100 No siRNA
CKAP4 siRNA
Non-target siRNA
APF [uM]
%
 
I
n
h
i
b
i
t
i
o
n
 
o
f
3
H
-
T
h
y
m
i
d
i
n
e
I
n
c
o
r
p
o
r
a
t
i
o
n
Figure 1 CKAP4 knockdown in T24 cells. A, Western blot analysis
of CKAP4 protein expression in cells electroporated in the presence
of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or
scrambled non-target (NT) siRNA (Lanes 5 and 6), and treated with
as-APF (APF) or its inactive control peptide (Pep). b-actin served as a
standard control. B, Inhibition of
3H-thymidine incorporation by as-
APF (APF) in cells electroporated with no siRNA, CKAP4 siRNA, or
non-target siRNA. Results are shown as percent inhibition of
3H-
thymidine incorporation compared to control cells that did not
receive as-APF treatment. Experiment was performed in triplicate
twice.
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Page 4 of 11cells. Although GSK3b ser9 phosphorylation may have
been minimally decreased in APF-treated nontransfected
and non-target siRNA-transfected cells response to APF,
GSK3b tyrosine 216 (tyr216) phosphorylation was clearly
decreased following APF treatment of these same
cells (but unchanged in CKAP4 siRNA-transfected cells)
(Figure 4A). Again, APF treatment did not appear to affect
total GSK3b protein (Figure 4A) or mRNA (Figure 4B-D)
expression, regardless of transfection status (p > .05 for all
PCR comparisons, including target gene mRNA relative to
b-actin or GAPDH mRNA; data shown for normalization
to b-actin expression, only). These findings indicate that
APF induces changes in GSK3b phosphorylation via
CKAP4, but further suggest that APF does not mediate its
antiproliferative activity in T24 cells merely by inhibiting
canonical Wnt/frizzled signaling.
We therefore proceeded to examine the effects of as-APF
on b-catenin and b-catenin phosphorylation in T24 cells.
As shown in Figure 5A, although subtle increases in b-cate-
nin phosphorylation were apparent following APF treat-
ment of nontransfected cells when antibodies against
phosphoserine 33, 37 and threonine 41 (ser33,37/thr41)
sites were used, there was no apparent change in total cell
b-catenin protein. In addition, decreased phosphorylation
was apparent following APF treatment when antibodies
that recognized phosphoserine 45 (ser45) and phospho-
threonine 41 (thr41) were used. Again, these changes in
phosphorylation were abrogated by CKAP4 knockdown,
and there were no significant differences in b-catenin
mRNA levels regardless of transfection status (Figure 5B-D)
(p > .05 for all PCR comparisons, including target gene
mRNA relative to b-actin or GAPDH mRNA; data shown
for normalization to b-actin expression, only). Although
these findings suggest subtle changes in b-catenin phos-
phorylation in response to APF, they also provide additional
evidence that APF may mediate its profound effects on cell
proliferation and gene expression via means other than
(or in addition to) regulation of canonical Wnt/frizzled
signaling pathways.
Downregulation of MMP2 expression by APF in T24
bladder cancer cells via CKAP4
Wnt/frizzled signaling is also known to stimulate cellu-
lar production of specific gelatinases including MMP2
[31,32] which has been implicated in HB-EGF activation
and cleavage [33] as well as the progression and/or
occurrence of various cancers including bladder cancer
[34-37]. As the expression of MMP2 is also known to
A
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Figure 2 p 5 3e x p r e s s i o ni nT 2 4b l a d d e rc a n c e rc e l l s . A, Western blot analysis of p53 protein expression in cells electroporated in the
presence of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or scrambled non-target (NT) siRNA (Lanes 5 and 6), and treated with as-
APF (APF) or its inactive control peptide (Pep). b-actin served as a standard control. B, Quantitative real time RT-PCR analysis of p53 mRNA
expression in T24 cells electroporated with no siRNA, C, CKAP4 siRNA, or D, non-target siRNA, and then treated with as-APF (APF) or its inactive
control peptide (Pep). Each experiment was performed in duplicate on at least three separate occasions. Data are expressed as mean ± SEM.
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next determined whether as-APF also regulated MMP2
expression in T24 cells.
As shown in Figure 6A, APF treatment decreased
MMP2 protein expression in nontransfected or non-target
siRNA-transfected, but not CKAP4 siRNA-transfected,
T24 cells. Similarly, APF treatment resulted in significantly
decreased MMP2 mRNA levels in nontransfected or non-
target transfected but not CKAP4 siRNA-transfected cells
(Figure 6B-D) (p < .01 for nontransfected and p < .05 for
non-target transfected cells, regardless of whether target
gene mRNA expression was calculated relative to b-actin
or GAPDH mRNA; data shown for normalization to
b-actin expression, only). These findings indicate that APF
inhibits MMP2 mRNA and protein expression in T24 cells
via CKAP4.
Discussion
The current study shows that APF mediates its antipro-
liferative effects in T24 bladder carcinoma cells via the
CKAP4 transmembrane receptor, as found previously
for normal bladder epithelial cells [27]. Further, it indi-
cates that the mechanism whereby APF inhibits bladder
carcinoma cell proliferation via CKAP4 involves the reg-
ulation of phosphorylation (with activation or inactiva-
tion) of various cell signaling molecules including Akt,
GSK3b, b-catenin, along with mRNA and protein
expression of p53 and MMP2.
CKAP4, which was first described as a reversibly pal-
mitoylated type II transmembrane receptor [28], was
previously shown to bind the synthetic form of a natural
bladder epithelial cell antiproliferative factor (as-APF)
and mediate its effects on normal bladder epithelial cell
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Figure 3 Akt phosphorylation activity in T24 bladder cancer cells. A, Western blot analysis of Akt protein expression and phosphorylation in
cells electroporated in the presence of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or scrambled non-target (NT) siRNA (Lanes 5 and
6), and treated with as-APF (APF) or its inactive control peptide (Pep). b-actin served as a standard control. B, Quantitative real time RT-PCR
analysis of Akt mRNA expression in T24 cells electroporated with no siRNA, C, CKAP4 siRNA, or D, non-target siRNA, and then treated with as-
APF (APF) or its inactive control peptide (Pep). Each experiment was performed in duplicate on at least three separate occasions. Data are
expressed as mean ± SEM.
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Page 6 of 11proliferation [27]. Results from the current study show
that the CKAP4 receptor is also required for inhibition
of bladder carcinoma cell proliferation by as-APF
in vitro. In addition, experiments performed to elucidate
the mechanism of APF activity indicate that this frizzled
8-related glycopeptide induces altered expression or
phosphorylation of certain proteins that differ in some
aspects from those seen in canonical Wnt/frizzled
signaling.
Downstream signal transducers for Wnt/frizzled sig-
naling include Akt, GSK3b, and b-catenin [39]. The ser-
ine threonine kinase Akt, also known as protein kinase
B (PKB), is a central regulator of cell proliferation, moti-
lity and survival whose activity is often altered in human
malignancies [40]. Akt mediates its downstream effects
via phosphorylation/inactivation of GSK3b ser9, with
subsequently decreased phosphorylation of the GSK3b
target b-catenin, resulting in increased b-catenin nuclear
translocation, binding to T-cell factor, and stimulation
of gene expression related to cell proliferation and survi-
val [30,41]. In addition to its association with malignant
cell proliferation, increased Akt phosphorylation/activa-
tion has also been linked to the invasive properties of
bladder cancer cells [40]. The inhibition of Akt ser473
and thr308 phosphorylation by APF suggests that APF
may profoundly inhibit bladder epithelial cell Akt activ-
ity, and therefore decrease bladder carcinoma cell inva-
sive potential, as well.
GSK3b activity is reduced by phosphorylation of ser9
but stimulated by phosphorylation on tyr216 [42], and
the downstream effects of Akt activation/phosphoryla-
tion during Wnt/frizzled signaling include increased
ser9 phosphorylation with decreased activity of GSK3b,
decreased GSK3b-inducedb-catenin ser33,37 phosphory-
lation, and subsequently decreased b-catenin ubiquitina-
tion and degradation. If as-APF mediated its activity in
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Figure 4 GSK3b tyr216 phosphorylation activity in bladder cancer cells. A, Western blot analysis of GSK3b p r o t e i ne x p r e s s i o na n d
phosphorylation in cells electroporated in the presence of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or scrambled non-target (NT)
siRNA (Lanes 5 and 6), and treated with as-APF (APF) or its inactive control peptide (Pep). b-actin served as a standard control. B, Quantitative
real time RT-PCR analysis of GSK3b mRNA expression in T24 cells electroporated with no siRNA, C, CKAP4 siRNA, or D, non-target siRNA, and
then treated with as-APF (APF) or its inactive control peptide (Pep). Each experiment was performed in duplicate on at least three separate
occasions. Data are expressed as mean ± SEM.
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Page 7 of 11T24 cells purely by inhibiting canonical Wnt/frizzled
signaling (like other secreted frizzled-related cell growth
inhibitors), GSK3b ser9 phosphorylation should have
been decreased substantially, while tyr216 phosphoryla-
tion (which may be mediated by mitogen-activated pro-
tein kinase kinase (MEK) 1/2) [43] should not have been
affected. Our results, which showed only a very minimal
decrease in GSK3b ser9 phosphorylation, but a substan-
tial decrease in GSK3b yr216 phosphorylation, indicate
that as-APF: 1) does not mediate its activity purely by
regulating Wnt/frizzled canonical signaling; 2) may inhi-
bit GSK3b and additional kinases (such as MEK 1/2);
and 3) may mediate its antiproliferative effects in T24
cells via inhibition of Akt, GSK3b,a n d / o rM E K 1 / 2
involving downstream effects on targets in addition to
b-catenin. Indeed, the modest increase in apparent
phosphorylation of b-catenin ser33,37/thr41, along with
a decrease in phosphorylation of b-catenin ser45 (which
is mediated by autophosphorylation, casein kinase 1,
and/or a complex of cyclin D1/cyclin-dependent kinase
6, and which primes ser33,37 for phosphorylation by
GSK3b) [42,44], suggests that the regulation of total
b-catenin protein and/or inhibition of canonical Wnt/
frizzled signaling may not be the sole mechanism by
which APF induces its effects on cell proliferation and
gene expression.
Matrix metalloproteinases (MMPs) are a multigene
family of zinc-dependent endopeptidases that degrade
extracellular matrix components, whose expression is
also regulated via Wnt/frizzled signaling pathways
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Figure 5 b-catenin phosphorylation in T24 bladder cancer cells. A, Western blot analysis of b-catenin protein expression and
phosphorylation activity in cells electroporated in the presence of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or scrambled non-
target (NT) siRNA (Lanes 5 and 6), and treated with as-APF (APF) or its inactive control peptide (Pep). b-actin served as a standard control. B,
Quantitative real time RT-PCR analysis of b-catenin mRNA expression in T24 cells electroporated with no siRNA, C, CKAP4 siRNA, or D, non-target
siRNA, and then treated with as-APF (APF) or its inactive control peptide (Pep). Each experiment was performed in duplicate on at least three
separate occasions. Data are expressed as mean ± SEM.
Shahjee et al. Journal of Experimental & Clinical Cancer Research 2010, 29:160
http://www.jeccr.com/content/29/1/160
Page 8 of 11[31,32] and has been shown to correlate with invasive
potential of many different tumors [45]. Expression of
MMP2 is associated with bladder carcinoma cell inva-
sion and metastasis [34-37]. The ability of as-APF to
significantly inhibit MMP2 mRNA and protein expres-
sion in T24 cells also suggests that as- A P Fm a yb ea b l e
to decrease the invasive potential of bladder carcinoma
cells as well as inhibit their proliferation.
Previous experiments performed by Jayoung Kim
showed that p53 mediated the antiproliferative effects of
native APF in both normal and T24 bladder carcinoma
cells [22]. The current study confirms this result by
showing that synthetic as-APF also increases p53 pro-
tein and mRNA expression in T24 cells, and it further
demonstrates the role of the CKAP4 receptor in APF-
induced p53 upregulation.
Although the expression or activation of each of the cell
proteins shown to be modified by APF can be regulated
via Wnt/frizzled pathways, the specific alterations seen in
Akt/GSK3b/b-catenin phosphorylation and the lack of an
effect of APF on total cellular b-catenin levels suggest that
this secreted frizzled-related peptide does not inhibit T24
bladder cell proliferation solely via inhibition of canonical
Wnt/frizzled signaling. Whether the CKAP4 receptor can
mediate transmembrane signaling, and/or whether it func-
tions as a chaperone protein for cytoplasmic or nuclear
translocation of APF, is unknown [27,29]. However, the
myriad effects of APF on cell protein activation and
expression discovered in the current as well as previous
studies [19,21] indicate it may inhibit cell proliferation by
regulating the activity of more than one signaling pathway
or transcriptional regulatory factor.
The ability of as-APF to inhibit GSK3b tyr216 phos-
phorylation without inhibiting GSK3b ser9 phosphoryla-
tion suggests it may also be a potent GSK3b enzyme
inhibitor in T24 cells. Recent studies on natural com-
pound GSK3b inhibitors suggest that this class of drugs
may be promising for the regulation of certain cancers
[46]. Additional in vitro and in vivo studies with this
intriguing natural frizzled 8-related glycopeptide are in
progress to elucidate further its important cell regulatory
function(s) as well as its potential as a therapeutic agent.
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Figure 6 MMP2 expression in T24 bladder cancer cells. A, Western blot analysis of MMP2 protein expression in cells electroporated in the
presence of no siRNA (Lanes 1 and 2), CKAP4 siRNA (Lanes 3 and 4), or scrambled non-target (NT) siRNA (Lanes 5 and 6), and treated with as-
APF (APF) or its inactive control peptide (Pep). b-actin served as a standard control. B, Quantitative real time RT-PCR analysis of MMP2 mRNA
expression in T24 cells electroporated with no siRNA, C, CKAP4 siRNA, or D, non-target siRNA, and then treated with as-APF (APF) or its inactive
control peptide (Pep). Each experiment was performed in duplicate on at least three separate occasions. Data are expressed as mean ± SEM.
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